{
    "clinical_study": {
        "@rank": "80617", 
        "arm_group": {
            "arm_group_label": "TAS-102 and CPT-11", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and determine the maximum tolerated\n      dose of TAS-102 administered in combination with CPT-11 in patients with advanced\n      gastrointestinal tumors."
        }, 
        "brief_title": "Study of the Safety of Escalating Doses of TAS-102 in Combination With CPT-11 in Patients With Advanced Gastrointestinal Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Gastrointestinal Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Digestive System Neoplasms", 
                "Gastrointestinal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, non-randomized, dose-escalation, Phase 1 study of TAS-102\n      administered in combination with CPT-11. The study will be conducted in 2 parts: a Dose\n      Escalation Phase (Part 1) to determine the maximum tolerated dose and an Expansion Phase\n      (Part 2) to further evaluate the safety, pharmacokinetics, and preliminary efficacy of the\n      maximum tolerated dose. Patients will be assigned to sequential dose-level cohorts with each\n      cohort corresponding to a pre-specified dose of TAS-102 and CPT-11 combination. Escalation\n      to the subsequent dose level will occur only after the previous dose level is determined to\n      be safe."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has advanced gastrointestinal tumors refractory to at least 1 chemotherapy and for\n             which no curative therapy exists\n\n          2. Has a malignancy of gastrointestinal origin or adenocarcinoma of unknown primary,\n             likely to be of GI origin\n\n          3. ECOG performance status of 0 or 1\n\n          4. Is able to take medications orally\n\n          5. Has adequate organ function (bone marrow, kidney and liver)\n\n          6. Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control.\n\n        Exclusion Criteria:\n\n          1. Has had certain other recent treatment e.g. major surgery, extended field radiation,\n             anticancer therapy, received investigational agent, within the specified time frames\n             prior to study drug administration\n\n          2. Certain serious illnesses or medical condition(s)\n\n          3. Has unresolved toxicity of greater than or equal to CTCAE Grade 1 attributed to any\n             prior therapies\n\n          4. Known sensitivity to TAS-102, CPT-11, or their components\n\n          5. Is a pregnant or lactating female\n\n          6. Refuses to use an adequate means of contraception (including male patients)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916447", 
            "org_study_id": "TPU-TAS-102-109"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAS-102 and CPT-11", 
                "description": "Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "TAS-102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TAS-102 and CPT-11", 
                "description": "Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "CPT-11", 
                "intervention_type": "Drug", 
                "other_name": "camptothecin-11, irinotecan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Camptothecin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Advanced gastrointestinal tumors refractory to at least 1 chemotherapy and for which no curative therapy exists", 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "contact": {
                "email": "saltzl@mskcc.org", 
                "last_name": "Leonard Saltz, MD", 
                "phone": "646-888-4181"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Leonard Saltz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 in Patients With Advanced Gastrointestinal Tumors", 
        "overall_contact": {
            "email": "aivado@taihopui.com", 
            "last_name": "Manuel Aivado, MD, PhD", 
            "phone": "855-598-8259"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Leonard Saltz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The maximum tolerated dose is defined as the highest dose level at which less than 33% of the evaluable patients treated experience a dose-limiting toxicity during Cycle 1 or Cycle 2 (ie, during the first 4 weeks) of study drug administration.", 
                "measure": "Determine maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "Through Cycle 1 and Cycle 2 (ie, 4 weeks)"
            }, 
            {
                "description": "Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be used.", 
                "measure": "Safety monitoring including adverse events, vital signs, and laboratory assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Safety is assessed through 30 days following last administration of study medication or until initiation of new anticancer treatment."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916447"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of TAS-102, CPT-11, and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Time to maximum plasma concentration (Tmax) of TAS-102, CPT-11, and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-last) of TAS-102, CPT-11, and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of TAS-102, CPT-11, and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Apparent terminal phase elimination half-life (t\u00bd) of TAS-102, CPT-11, and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Clearance (CL/F) of TAS-102", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Apparent volume of distribution (Vd/F) of TAS-102", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in Cycle 1 at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 hours after administration of TAS 102 in combination with CPT 11"
            }, 
            {
                "measure": "Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "After every 4 cycles (ie, every 8 weeks) through Cycle 24 (ie, 48 weeks) or as clinically necessary."
            }
        ], 
        "source": "Taiho Oncology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taiho Oncology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}